A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive

NCT04528719 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

651

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

BIOLOGICAL: mRNA-1345
DRUG: Placebo

Sponsor

ModernaTX, Inc.